1. Home
  2. FSHP vs AVTX Comparison

FSHP vs AVTX Comparison

Compare FSHP & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSHP
  • AVTX
  • Stock Information
  • Founded
  • FSHP 2018
  • AVTX 2011
  • Country
  • FSHP United States
  • AVTX United States
  • Employees
  • FSHP N/A
  • AVTX N/A
  • Industry
  • FSHP
  • AVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSHP
  • AVTX Health Care
  • Exchange
  • FSHP NYSE
  • AVTX Nasdaq
  • Market Cap
  • FSHP 90.7M
  • AVTX 88.4M
  • IPO Year
  • FSHP 2024
  • AVTX 2015
  • Fundamental
  • Price
  • FSHP $10.23
  • AVTX $7.35
  • Analyst Decision
  • FSHP
  • AVTX Strong Buy
  • Analyst Count
  • FSHP 0
  • AVTX 4
  • Target Price
  • FSHP N/A
  • AVTX $33.00
  • AVG Volume (30 Days)
  • FSHP 7.1K
  • AVTX 55.8K
  • Earning Date
  • FSHP 01-01-0001
  • AVTX 03-28-2025
  • Dividend Yield
  • FSHP N/A
  • AVTX N/A
  • EPS Growth
  • FSHP N/A
  • AVTX N/A
  • EPS
  • FSHP 0.11
  • AVTX N/A
  • Revenue
  • FSHP N/A
  • AVTX $820,000.00
  • Revenue This Year
  • FSHP N/A
  • AVTX N/A
  • Revenue Next Year
  • FSHP N/A
  • AVTX N/A
  • P/E Ratio
  • FSHP $90.07
  • AVTX N/A
  • Revenue Growth
  • FSHP N/A
  • AVTX N/A
  • 52 Week Low
  • FSHP $9.99
  • AVTX $4.18
  • 52 Week High
  • FSHP $10.25
  • AVTX $34.46
  • Technical
  • Relative Strength Index (RSI)
  • FSHP N/A
  • AVTX 42.79
  • Support Level
  • FSHP N/A
  • AVTX $7.42
  • Resistance Level
  • FSHP N/A
  • AVTX $8.50
  • Average True Range (ATR)
  • FSHP 0.00
  • AVTX 0.64
  • MACD
  • FSHP 0.00
  • AVTX 0.02
  • Stochastic Oscillator
  • FSHP 0.00
  • AVTX 17.16

About FSHP FLAG SHIP ACQUISITION CORPORATION

Flag Ship Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Share on Social Networks: